173 related articles for article (PubMed ID: 37975877)
21. Three years of paediatric regulation in the European Union.
Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
[TBL] [Abstract][Full Text] [Related]
22. Paediatric drug development and evaluation: Existing challenges and recommendations.
Kaguelidou F; Ouèdraogo M; Treluyer JM; Le Jeunne C; Annereau M; Blanc P; Bureau S; Ducassou S; Fiquet B; Flamein F; Gaillard S; Hankard R; Laugel V; Laurent C; Levy C; Marquet T; Polak M; Portefaix A; Vassal G
Therapie; 2023; 78(1):105-114. PubMed ID: 36528416
[TBL] [Abstract][Full Text] [Related]
23. New Information on Old Medicinal Products: A Cross-Sectional Analysis of Guidance for Paediatric Use for Substances on the European Priority List of Off-Patent Medicinal Products.
Mogensen AB; Christiansen H; De Bruin ML; Hallgreen CE
Paediatr Drugs; 2022 Nov; 24(6):679-687. PubMed ID: 35962257
[TBL] [Abstract][Full Text] [Related]
24. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
Vassal G; de Rojas T; Pearson ADJ
Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
[TBL] [Abstract][Full Text] [Related]
25. ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?
Pearson ADJ; de Rojas T; Karres D; Reaman G; Scobie N; Fox E; Lesa G; Ligas F; Norga K; Nysom K; Pappo A; Weigel B; Weiner S; Vassal G
Lancet Oncol; 2022 Nov; 23(11):1354-1357. PubMed ID: 36328007
[No Abstract] [Full Text] [Related]
26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
27. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer - An ACCELERATE Multistakeholder Consensus.
de Rojas T; Chiodin D; Pearson ADJ; Heenen D; Adamson P; Caron H; Vassal G
Clin Pharmacol Ther; 2024 Jan; 115(1):36-41. PubMed ID: 37885401
[TBL] [Abstract][Full Text] [Related]
28. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
29. Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer.
Vassal G; Kearns P; Blanc P; Scobie N; Heenen D; Pearson A
Eur J Cancer; 2017 Oct; 84():149-158. PubMed ID: 28818704
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular Paediatric Medicines Development: Have Paediatric Investigation Plans Lost Heart?
Faulkner B; Delgado-Charro MB
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33276598
[TBL] [Abstract][Full Text] [Related]
32. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
[TBL] [Abstract][Full Text] [Related]
33. Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA.
Cavaller-Bellaubi M; Hughes-Wilson W; Kubinová Š; Van de Casteele M; Van Lente EJ; Degortes E; Pontén J; Eichler HG; Le Cam Y; Boselli S; Bucsics A
Orphanet J Rare Dis; 2023 Jun; 18(1):144. PubMed ID: 37308991
[TBL] [Abstract][Full Text] [Related]
34. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
Rose K; Senn S
Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
[TBL] [Abstract][Full Text] [Related]
35. Strategies to facilitate adolescent access to medicines: Improving regulatory guidance.
Bucci-Rechtweg C; Siapkara A; An Haack Bonnet K; Corriol Rohou S; Haf Davies E; Dehlinger Kremer M; Gamalo M; Moreno C; Nelson RM; Thomas Turner R
Clin Trials; 2023 Feb; 20(1):13-21. PubMed ID: 36341541
[TBL] [Abstract][Full Text] [Related]
36. Orphan Medicines for Pediatric Use: A Focus on the European Union.
Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
[TBL] [Abstract][Full Text] [Related]
37. Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents.
Vassal G; Méry-Mignard D; Caulin C
Therapie; 2003; 58(3):229-46. PubMed ID: 14655318
[TBL] [Abstract][Full Text] [Related]
38. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
39. Intercontinental collaboration in clinical trials for children and adolescents with cancer-A systematic review by ACCELERATE.
de Rojas T; Pearson AJ; Scobie N; Knox L; Wariabharaj D; Kearns P; Vassal G; Reaman G
Cancer Med; 2021 Dec; 10(23):8462-8474. PubMed ID: 34687165
[TBL] [Abstract][Full Text] [Related]
40. Role of modeling and simulation in pediatric investigation plans.
Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
